WCLC 2024: A Phase Ib Study to Evaluate HMBD‑001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers, and HMBD‑001 in Combination with Cetuximab in Participants with Advanced Squamous Cell Cancers